CEACAM1, also known as C-CAM, BGP and CD66a, is a member of the carcinoembryonic antigen (CEA) family which is itself part of the immunoglobulin supergene family. CEACAM1 is involved in intercellular adhesion, signal transduction and tumor cell growth regulation. CEACAM1 is down-regulated in colon and prostate carcinomas, as well as in endometrial, bladder and hepatic tumors, and 30% of breast cancers. We have shown in a mouse colon tumor model that CEACAM1 with a long cytoplasmic domain inhibited the development of tumors whereas a splice variant lacking the cytoplasmic domain did not. In this study, we de®ne the subregions of the long cytoplasmic domain participating in the tumor inhibition phenotype of CEACAM1. We show that a single point mutation of Tyr488, conforming to an Immuno-receptor Tyrosine Inhibition Motif (ITIM), was sucient to reverse the in vivo tumor cell growth inhibition. Substitution or deletion of residues in the C-terminal region of the CEACAM1 cytoplasmic domain also led to reversal of tumor cell growth inhibition. This result is in agreement with our previous studies demonstrating the C-terminal region of the cytoplasmic domain in¯uences the levels of CEACAM1 Tyr phosphorylation and its association with the protein Tyr phosphatases SHP-1 and SHP-2. Furthermore, removal of the N-terminal domain of CEACAM1, essential for intercellular adhesion, did not impair the tumor inhibitory eect. These results suggest that Tyr phosphorylation or dephosphorylation of the CEACAM1 cytoplasmic domain represents a crucial step in the control of epithelial cell proliferation.
Introduction
Colorectal tumor development is a consequence of the dysregulation or alteration of a number of key cellular proteins. Amongst them are oncogenes such as ras, tumor suppressors such as the APC and p53 proteins Shibata et al., 1997) , and proteins involved in TGF-b signaling such as Dpc4 (Smad4) (Thiagalingam et al., 1996; Moskaluk and Kern, 1996) . Compound mutations, such as those observed in Apc and Smad4 proteins, also have an additive eect on colorectal tumor development (Takaku et al., 1998) .
We and others have shown that another cell adhesion molecule identi®ed as biliary glycoprotein 1 (BGP in human, Bgp1 in mouse), is implicated in colorectal tumor development (Neumaier et al., 1993; Rosenberg et al., 1993; Kunath et al., 1995) . BGP is a member of the carcinoembryonic antigen (CEA) family (Hinoda et al., 1988) . The nomenclature of this gene family has recently been rede®ned and the C-CAM or BGP proteins are now referred to as CEACAM1 proteins . The CEACAM1 protein is abundantly expressed in normal colonic tissue and is generally concentrated in the luminal glycocalyx and fuzzy coat of the intestinal epithelial cells (FraÈ ngsmyr et al., 1995) . In addition, the CEACAM1 protein is also found at the lateral borders of enterocytes (Hansson et al., 1989) . However, upon cellular transformation, the CEACAM1 expression is down-regulated in colonic tissue (Rosenberg et al., 1993; Neumaier et al., 1993) . This occurs at an early period in tumor development as intestinal adenomas (Nollau et al., 1997; Ilantzis et al., 1997) or stage A tumors are devoid of CEACAM1 expression (Rosenberg et al., 1993) . This is not unique to colonic tissue, since CEACAM1 expression is also decreased in hyperplastic prostatic and mammary glands (Kleinerman et al., 1995a; Riethdorf et al., 1997) , in transformed hepatic tissue (Hixson et al., 1985; Tanaka et al., 1997) and in bladder and endometrial tumors Bamberger et al., 1998) . Interestingly, this protein has also been identi®ed by the SAGE technique as a down-regulated participant in colorectal tumor development (Zhang et al., 1997) . However, primary lung tumors (squamous cell carcinoma, adenocarcinoma and small cell carcinoma) and stomach tumors overexpress the CEACAM1 protein (Ohwada et al., 1994; Kinugasa et al., 1998) . Interestingly, in mestastatic lesions of these lung cancers, CEACAM1 mRNA expression is decreased compared to the primary site (Ohwada et al., 1994) .
The CEACAM1 gene lies on human chromosome 19q13.1-2 ( Thompson et al., 1991) or mouse chromosome 7 (Robbins et al., 1991) . There is only one human and rat CEACAM1 gene (Barnett et al., 1989; Najjar et al., 1993) , but two very similar genes have been identi®ed in the mouse (Ceacam1 and Ceacam2) (NeÂ dellec et al., 1994 (NeÂ dellec et al., , 1995 . The CEACAM1 genes in all three species generate a signi®cant number of alternative splicing variants. The extracellular domains form typical Ig folds with one variable Ig-like domain and one to three C2-set Ig-like domains (Barnett et al., 1989) . The most conserved feature between the CEACAM1 gene products of various species is found in their cytoplasmic region. Insertion of exon 7, comprised of 53 bp, into the CEACAM1 mRNA leads to the translation of a protein with a long cytoplasmic domain of 71 ± 73 amino acids (denoted L), while its absence creates a cytoplasmic tail of ten residues (identi®ed as S). Both forms are tandemly expressed in most CEACAM1-positive tissues in a characteristic ratio ranging from 1-3L : 7-9S (Lin and Guidotti, 1989; Turbide et al., 1997) .
We have demonstrated that insertion of the CEACAM1 protein into highly tumorigenic and metastatic mouse CT51 colon carcinoma cells led to inhibition of tumor cell growth in vitro and in vivo in BALB/c syngeneic mice (Kunath et al., 1995) . A major dierence was noticed however, between the CEA-CAM1 isoforms: only the CEACAM1 splice variant expressing the long cytodomain possessed tumor inhibitory activity. Similar results were obtained by studying a rat CEACAM1 variant in a prostatic PC-3 carcinoma model (Hsieh et al., 1995) . In addition, down-regulation of CEACAM1 expression in nontumorigenic ventral prostatic NbE cells by antisense technology induced the development of anaplastic and poorly-dierentiated tumors when transfected cells were injected in vivo (Hsieh et al., 1995) . As CEACAM1-L and -S are both expressed in normal cells, we questioned if changing the expression ratio of these isoforms would in¯uence tumor development. We found that as long as the ratio of CEACAM1-S : CEACAM1-L was similar to that found in normal cells, tumor development was inhibited. However, reversing the ratio led to the formation of tumors with shortened latency .
Using deletion and point mutations within the CEACAM1 long cytoplasmic domain, we have now delineated some of the sequence elements within this region responsible for colonic tumor cell growth inhibition. Our results indicate that Tyr488 and a number of C-terminal residues of the CEACAM1 cytoplasmic domain play a major role in the tumor inhibition phenotype, whereas mutation of Tyr515 to Phe was inconsequential. In addition, we demonstrate that deletion of the N-terminal domain of the CEACAM1 protein, instrumental in mediating intercellular adhesion, did not in¯uence its tumor inhibitory phenotype. We conclude that the CEA-CAM1 cytoplasmic domain may probably adopt a particular conformation in vivo favoring cooperation of Tyr488 and C-terminal Lys519-521 in mediating the tumor inhibition phenotype or that several cytoplasmic proteins, normally binding to these regions exert their phenotypic eects by altering the signal transduction cascades leading to increased cell proliferation.
Results

Expression of CEACAM1 proteins
We and others have already shown that the CEACAM1 proteins are expressed in normal tissues such as colon and liver (Rosenberg et al., 1993; Ocklind and O È brink, 1982) . However, CEACAM1 expression is lost or greatly reduced in colonic, prostatic, breast, hepatic and endometrial carcinomas (Kunath et al., 1995; Hsieh et al., 1995; Luo et al., 1997; Tanaka et al., 1997; Bamberger et al., 1998) . In addition, the tumor inhibitory phenotype is dependent on the long cytoplasmic domain of CEACAM1-L and not on the shorter variant, CEACAM1-S (Kunath et al., 1995; Turbide et al., 1997) .
We sought to de®ne carboxy-terminal subregions or residues within the long cytoplasmic isoform responsible for tumor cell growth inhibition. To attain our objectives, several C-terminal and N-terminal deletion mutants were generated (Figure 1 ). The following mutants were devised to establish the impact of Tyr phosphorylation and/or dephosphorylation on CEA-CAM1-dependent tumor inhibition: CEACAM1Y488F, Y515F and Y488,515F, D483 (Figure 1 ). CEACAM1/ D518, in which the last three Lys residues were eliminated, was generated to determine the involvement of these residues in tumor cell growth inhibition (Figure 1) . A CEACAM1 triple point (3K?3R) was produced to verify if the charge of the terminal Lys residues was important in this phenotype (Figure 1) . We have recently shown that the Val at position 518 is important for the association of CEACAM1-L to the SHP-2 protein Tyr phosphatase (Huber et al., 1999) ; therefore, a CEACAM1 protein exhibiting a Val to Ala substitution at position 518 (CEACAM1/V518A) was included in our assays to evaluate its role in tumor inhibition. CEACAM1 has also been identi®ed as an intercellular adhesion molecule (McCuaig et al., 1992) . In this regard, we have questioned the role of the extracellular domain responsible for cell adhesion by studying the tumorigenicity of N-terminal deletion mutants (D4-122/S and D4-122/L).
The cDNAs corresponding to these CEACAM1 proteins were inserted in CT51 colon carcinoma cells by retroviral-mediated infections. Enrichment of cells expressing the CEACAM1 proteins was performed by immunoselection using anti-CEACAM1 polyclonal antibodies (Ab231 or 655) and Dynabeads
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. Total CEACAM1 protein expression was evaluated by immunoblotting analyses (Figure 2a) . The CEA-CAM1 proteins migrated as large heterogeneous bands due to their high content of glycosylated residues (16 Asn-linked carbohydrate moieties in the wild-type CEACAM1 isoform). Within this large band, there appears to be two major entities ( Figure  2a , ®rst panel, Y488F or Y515F), most possibly corresponding to predominant glycoforms synthesized in this cell line. CEACAM1-S appeared as a band at &120 kDa, whereas CEACAM1-L had a relative molecular weight of approximately 128 kDa. The CEACAM1/D4-122L and -D4-122S mutants migrated as proteins of approximately 95 kDa. The use of Ab655 was necessary for detection in this case, as Ab231 only recognizes epitopes in the N-terminal domain of the CEACAM1 proteins (Daniels et al., 1996) . All other mutants exhibited a relative molecular weight between 120 and 128 kDa. Radioactive quantitations of several representative experiments revealed that the CEACAM1 proteins were overexpressed by factors ranging from 1.2 ± 9.1 relative to the band of lowest intensity on each immunoblot (Figure 2a) . The tumor inhibitory properties of the CEACAM1 proteins may be related to their localization at the cell surface; therefore, cell surface expression of CEACAM1 proteins was estimated through cyto¯uorometric analyses. FACS pro®les showed that the cell populations or clones used in our assays overexpressed the CEACAM1 proteins by factors ranging between 1.9 and 6.7 relative to the background¯uorescence ( Figure 2b ). The expression levels of these mutants thus corresponded to the relative levels of expression of CEACAM1 found in normal colon .
Although the data calculated from¯uorescence pro®les and radioactive quantitations cannot be directly compared, it is apparent that most cell populations expressed the CEACAM1 proteins in the same relative range. Surface expression of the CEACAM1 proteins was comparable to the expression of CEACAM1 found in normal colonic cells . However, some discrepancies between the two dierent estimates were noticed with the CEACAM1/D518 and the CEACAM1/D4-122L and the /D4-122S mutant proteins. It is possible that a non-negligible amount of the CEACAM1/D518 protein expressed may not reach the cell surface. As for the variation observed with the CEACAM1/D4-122L and -S mutant proteins, the speci®city of antibody used (Ab655) may be responsible for the observed dierences.
Tyr488 of CEACAM1 plays a major role in tumor growth inhibition
According to recent reports, CEACAM1-L participates in signal transduction events Hauck et al., 1998; Huber et al., 1999) . CEACAM1-L contains two consensus ImmunorecepTyrosine-based Inhibition Motifs (ITIM) (Burshtyn et al., 1996) where either Tyr residue is phosphorylated by protein Tyr kinases, such as Src in human colon carcinoma cells (BruÈ mmer et al., 1995) , Lyn and Hck in activated neutrophils (Skubitz et al., 1995) and the insulin receptor in hepatocytes (Rees-Jones and Taylor, 1985) . CEACAM1-L Tyr phosphorylation is physiologically relevant during neutrophil respiratory bursts (Skubitz et al., 1995) , activation of neutrophils after binding of N. gonorrhea opa proteins to CEACAM1-L (Hauck et al., 1998) and in internalization of the insulin receptor (Formisano et al., 1995) . We have demonstrated that, in mouse CT51 colon carcinoma cells, the presence of both CEA-CAM1-L Tyr residues and the phosphorylation of at least one of them are required for association with the protein Tyr phosphatases SHP-1 and SHP-2 Huber et al., 1999) . Thus, we assessed the role of CEACAM1-L Tyr residues in tumor growth inhibition by testing single and double point mutants of Tyr488 and Tyr515 in in vivo tumor assays. Two completely independent experiments were performed, i.e. expression of CEACAM1-L mutant proteins in CT51 cells, isolation of CT51-transfected mutant sub-populations, and injection of cells in BALB/c syngeneic mice. As expected, the CT51 parental cells, the CT51 neo-transfected control cells and the CEACAM1-S-expressing CT51 cells readily formed tumors when injected in mice ( Figure 2 Expression of CEACAM1 proteins in CT51 colonic tumor cells. CT51 and neo3 are respectively wild-type and control transfected cells. CEACAM1-L represents the CT51 cell population expressing the long-tailed-CEACAM1 isoform. CEACAM1-S is a population expressing the short tailed-CEACAM1 isoform. D518, 3K?3R, V518A, Y488F, Y515F, Y488,515F, D4-122-L and D4-122-S are CT51 populations expressing mutant CEACAM1 proteins. (a) CT51 parental, neo3 control or CT51 cells expressing CEACAM1 proteins were analysed by immunoblotting. Cells were lysed and 100 mg of total cellular proteins were resolved on 8.0% SDS ± PAGE gels. Proteins were transferred to membranes which were incubated with rabbit anti-CEACAM1 antibodies (231 or 655) and 125 I-labeled protein A. Bands were subjected to radioactive quanti®cation. Molecular weight markers are illustrated on the left of the panel. The arrowhead on the left of the third panel indicates the presence of a non-speci®c band whereas the arrows on the right represent the full length CEACAM1-L or D4-122 mutants. (b) Surface expression of CEACAM1 proteins were evaluated by cyto¯uorometry using anti-CEACAM1-speci®c rat monoclonal antibody (AgB10). Fluorescence is depicted on a log scale. Dashed lines represent cells incubated with the secondary¯uorescein-labeled antibody only, whereas solid lines illustrate cells incubated with both primary (AgB10) and secondary antibodies CEACAM1 in tumor inhibition L Izzi et al control transfected cells were mostly used. As described previously, the expression of CEACAM1-L in CT51 cells reduced the development of tumors; 10 out of 25 mice injected with these cells exhibited tumor growths in these experiments (corresponding to an inhibition of 60%), whereas the majority of mice injected with control cells developed tumor growths (Table 1a) . Eects of the C-terminal region of CEACAM1-L in tumor development
In addition to the Tyr phosphorylation sites, other motifs are present in the C-terminal region of the long cytoplasmic tail such as a protein kinase C consensus site (Ser503) (Lin and Guidotti, 1989; Sippel et al., 1994) and a calmodulin binding site (Edlund et al., 1996) . In order to de®ne motifs, other than the ITIMs, involved in colonic tumor development, several mutations were introduced in the C-terminus of CEACAM1-L. One of the conserved features between the rodent and human cytoplasmic domains is the presence of three terminal Lys residues at the Cterminus of the protein. Huber et al. (1999) have shown that the C-terminal region in¯uences the extent of CEACAM1-L Tyr phosphorylation. The three Lys residues were removed to generate CEACAM1/D518. Deletion of the Lys residues reversed the tumor inhibition phenotype exhibited by CEACAM1-L (Table 1c) . Seventeen out of 20 mice injected with cells expressing this mutant developed tumors (Table  1c , P40.05 relative to neo3). To determine if the tumor inhibitory action of wild-type CEACAM1-L was due to the identity or the charge of the residues, an additional mutant was tested in which the three Lys residues were replaced by three Arg. When injected in BALB/c mice, CT51 cells expressing CEACAM1/ 3K?3R easily formed tumors. In fact, 16 out of 20 mice developed abnormal growths, (Table 1c , P40.05 relative to neo3). Hence, this result suggested that the presence of the three terminal Lys residues is important for CEACAM1-L's anti-proliferative eect. Huber et al. (1999) also showed that replacing Val518 by an Ala prevented SHP-2 association with CEACAM1-L, although this mutant had no signi®cant eect on the Tyr phosphorylation status of the protein. CT51 cells expressing CEACAM1/V518A were included in our tumorigenicity assays to determine the importance of this residue in tumor inhibition. Fourteen out of 20 mice injected with this cell population presented tumors (Table 1c , P40.05 relative to neo3). This result hints that Val518 in¯uences the CEA-CAM1-L-dependent tumor inhibition.
The mouse CEACAM1 intercellular adhesion domain is not involved in its tumor inhibitory eects CEACAM1 has been shown by several groups to function as an intercellular adhesion molecule (OcklinD and O È brink, 1982; Rojas et al., 1990; Oikawa et al., 1992; McCuaig et al., 1992) . In the rat and human CEACAM1 protein, the ®rst Ig domain is responsible for CEACAM1-dependent cell ± cell aggregation (Cheung et al., 1993; Watt et al., 1994) . We questioned whether the mouse CEACAM1 also used this same domain for intercellular binding. To this end, deletion mutants lacking the ®rst Ig domain (D4-122/S or D4-122/L) (Dveksler et al., 1993) were transfected into NIH3T3 ®broblasts and tested in aggregation assays (Figure 3) . The ®broblast cellular background was chosen for these experiments as these cells do not form aggregates, whereas the CT51 cells express the Ecadherin cell adhesion molecule (data not shown) and tend to form clumps. Parental NIH3T3 cells or cells transfected with an empty vector were used as negative controls, whereas CEACAM1-S-and CEACAM1-Ltransfected NIH3T3 cells represented the positive controls. After 2 h incubations at 378C, 86% of wildtype NIH3T3 cells and approximately 90% of CEACAM1/D4-122/L-or -/S-expressing cells were non-aggregated (Figure 3) . Comparatively, 65% of cells expressing CEACAM1-L or 50% of those transfected with CEACAM1-S remained single (Figure 3) . This con®rms that the ®rst Ig domain is responsible for the adhesive properties of the mouse CEACAM1.
To clarify the role of the adhesion domain in tumor growth suppression, CT51 cells expressing the Nterminal deletion mutants were introduced into BALB/c syngeneic mice. Tumor development was not inhibited by cells expressing the CEACAM1/D4-122/S mutant. This is consistent with the lack of signi®cant tumor inhibition seen with the CEACAM1-S-producing cells (16%, P40.05, relative to neo3) (compare results in Table 1d versus those in Table 1a ). On the other hand, CEACAM1/D4-122/L prevented tumor proliferation by 50%, also concurring with the 60% tumor inhibitory action of the full-length CEACAM1- 
Discussion
The results presented in this report focus on the motifs or domains of the CEACAM1 glycoprotein involved in inhibition of in vivo colonic tumor cell growth. The tumor growth inhibition role played by this glycoprotein in various diseased epithelial tissues is likely to be similar since CEACAM1 is down-regulated or absent in a number of malignancies such as intestinal, hepatic, prostate, breast, endometrial and bladder cancers (Kunath et al., 1995; Hsieh et al., 1995; Luo et al., 1997; Tanaka et al., 1997; Bamberger et al., 1998) . The evidence for its down-regulation is convincing in early stages of some cancers i.e. intestinal adenomas (Nollau et al., 1997) , hyperproliferative prostate tissue (Kleinerman et al., 1995a) or hepatic or breast tumors (Tanaka et al, 1997; Riethdorf et al., 1997) . However, CEACAM1 down-regulation does not appear to represent an all or nothing phenomena; it appears that there may be dierences in the cellular behavior of this protein, as CEACAM1 is overexpressed in at least two types of cancers i.e. lung and gastric carcinomas (Ohwada et al., 1994; Kinugasa et al., 1998) . Moreover, most human colon tumor cell lines tested express CEACAM1 abundantly (Barnett et al., 1989) . Cell surface expression of CEACAM1 seems therefore to be actively modulated; however, the responsible mechanisms have so far remained ill-de®ned. In this respect, CEACAM1 may not qualify as a`classical' tumor suppressor protein. Formisano et al. (1995) have reported that the phosphorylation of CEACAM1 correlates with internalization of the insulin receptor. In addition, Tyrphosphorylated CEACAM1 has been implicated in the activation of Rac1, PAK and Jun kinase in N. gonorrhea-activated neutrophils (Hauck et al., 1998) as well as in respiratory bursts in neutrophils (Skubitz et al., 1995) . Association of CEACAM1 with protein tyrosine kinases of the Src family (BruÈ mmer et al., 1995; Skutbitz et al., 1995) and with the protein tyrosine phosphatases SHP-1 and SHP-2 Huber et al., 1999) argues in favor of its involvement in signaling. CEACAM1 may either respond to or be involved in activation of a number of signal transduction cascades.
In light of this, we surmised that CEACAM1-L Tyrphosphorylation could impact upon the role of this glycoprotein in inhibition of tumor cell growth. In our analyses, a single point mutation of the Tyr488 residue was sucient to convert the inhibitory eect of the wild-type protein to that of a dominant tumor developing phenotype. In this case, tumors developed in all mice tested. In contrast, mutation of Tyr515 did not signi®cantly aect the inhibition of tumor cell growth. Each CEACAM1 Tyr residue may be involved separately in intermolecular cross-talk (i.e. speci®c protein ± protein interactions) requiring some degree of coordination for an overall eect to be produced. This would aect dierent signaling cascades which may antagonize each other. CEACAM1 Tyr residues may also be involved in some intramolecular interactions within the cytoplasmic domain, possibly requiring phosphorylation of the Tyr or Ser residues for eective folding of the cytoplasmic tail. The dominant tumor growth inhibitory role of Tyr488 is in complete agreement with a recent report identifying the role of Tyr488 as an ITIM motif in DT40 B cells: a chimera composed of Fcg receptor IIB fused to the cytoplasmic domain of human CEACAM1 inhibited calcium in¯ux in these cells, as did the wild-type receptor. The eect was abrogated by a mutation at Tyr488 and reduced in SHP-1-or SHP-2-de®cient DT40 B cells (Tie Chen et al., submitted).
Our results with Tyr488 are in contrast with those published by Luo et al. (1997) . In that report, Tyr488 of the rat C-CAM1 homologue was mutated to a Phe and expressed into the MDA-MB-468 human breast tumor cell line using adenoviral infections. Tumorigenicity assays were performed in nude mice. In these assays, CEACAM1/Y488F behaved like the wild-type protein. Whether the discrepancies in these analyses are due to dierential modulation of the protein in the breast versus the colonic tumor cell lines or to the amount of protein expressed at the cell surface remains to be evaluated. We have shown that truncation of the CEACAM1 cytoplasmic domain at residue 518, eliminating the three C-terminal lysines, provoked a reduction in its Tyr phosphorylation and a decrease in its association with the protein Tyr phosphatases SHP-1 and SHP-2 (Huber et al., 1999) as well as reversing the inhibition of tumor cell growth. Hence, mutations within CEACAM1 leading to abrogation or diminution of its overall Tyr-phosphorylation levels appear critical for the proliferation of cellular growth in vivo and the development of tumors. These results also reinforce the notion that association of the SHP-1 and/ or SHP-2 Tyr phosphatases to the CEACAM1 Tyrphosphorylated protein and their subsequent dephosphorylation of this substrate may then provoke a switch of these epithelial cells from the growth inhibitory mode to that of active proliferation.
The last residues of C-terminal end of CEACAM1 are important in tumor cell growth inhibition. Most mutations introduced within these residues (D518, V518A or 3K?3R) led to the development of tumors. Interestingly, this region of the cytoplasmic domain, which contains the potential ITIM sequence (pYXXV) (Huber et al., 1999) , is one of the most conserved across species (Beauchemin and Lin, 1998) . This region may also be involved in protein ± protein interactions. A calmodulin binding site overlaps with the C-terminal end of CEACAM1-L region (Edlund et al., 1996) . Truncation of the last 39 amino acids of the rat CEACAM1 homologue abrogates the binding of an unknown 80 kDa protein (Luo et al., 1998) . Its binding appears important for tumor cell growth inhibition. Clearly, more studies are necessary to understand the mechanisms governing tumor cell growth inhibition mediated by the CEACAM1 C-terminal region.
Our results also indicate, as previously shown with the rat and the human CEACAM1 proteins (Cheung et al., 1993; Watt et al., 1994) , that the ®rst Ig domain of the mouse CEACAM1 glycoprotein encodes the intercellular adhesion domain. However, the N-terminal domain does not apparently play a role in inhibition of colonic tumor development as a CEACAM1 deletion mutant excluding this domain retained its growth inhibition potential providing that the construct expressed the long cytoplasmic tail. A similar result has been obtained in a prostate cancer model (Luo et al., 1997) . Although the adhesion domain appears dispensable for the tumor inhibition phenotype, the role of the other extracellular Ig domains or the membrane-anchorage of this glycoprotein remains to be de®ned relative to tumor inhibition. In this respect, a parallel between the cadherins, another class of cell adhesion molecules, and CEA-CAM1 could be invoked to explain some of our ®ndings. We have recently shown using a variety of techniques that the CEACAM1 long cytoplasmic domain is connected with the actin cytoskeleton in the CT51 epithelial cells. In addition, microinjections of the CEACAM-1-L cDNA into con¯uent Swiss 3T3 ®broblasts indicate that this glycoprotein is associated with the actin cytoskeleton. Localization of CEA-CAM1-L to sites of cell ± cell contacts depends upon the activation of the Rho-like GTPases (Sadekova, Lamarche, Li and Beauchemin, submitted) . This family of GTP-binding proteins are actively involved in modulation of cell morphology, dierentiation programs and cell motility (Hall, 1998) . The cadherins are also tightly associated with the actin cytoskeleton via the catenins (Takeichi, 1988 (Takeichi, , 1991 . Loss of cadherin and b-catenin expression has been well documented in intestinal cancer . In fact, disruption of the cadherin-mediated signaling pathways leads to overt intestinal malignancies; these eects are highly dependent upon the sequestration of b-catenin away from the cadherins resulting in the loss of epithelial integrity (Pennisi, 1998) . As with the cadherins, it appears that cytoskeletal associations of CEACAM1-L takes precedence over its function as a cell adhesion molecule relative to tumor inhibition. Many questions will, however, need further investigation. For instance, does the down-regulation of CEACAM1 in epithelially-derived cancers early in the transformation process lead to major cytoskeletal reorganizations? Are these events conducive to greater mobility of the epithelial cells or altered dierentiation programs? Do CEACAM1 7/7 -engineered mice develop more tumors than their normal littermates? These represent some of the issues that we are currently studying. However, one important point has already deserved some attention: expression of CEACAM1 via adenoviral infections in an in vivo prostate tumor model is maintained long after the virus has disappeared, making this protein an interesting candidate for gene therapy trials (Kleinerman et al., 1995b) . This suggests that the mechanisms underlying the role of CEACAM1 in cellular growth control are crucial.
Materials and methods
Cell culture
The mouse CT51 colon carcinoma cells used in these experiments were a kind gift of Dr Michael G Brattain, (Medical College of Ohio, Toledo, Ohio) (Brattain et al., 1980) . CT51 cells were established from transplantable chemically-induced tumors in BALB/c mice. When injected subcutaneously in BABL/c syngeneic mice, these cells form tumors readily. Parental and transfectant cells were maintained in a-modi®ed Eagle's medium supplemented with 10% fetal bovine serum (Gibco ± BRL, Hamilton, Ontario, Canada), 50 units/ml of penicillin, 50 mg/ml streptomycin at 378C in 5% CO 2 -humidi®ed air. Transfectant cells were selected and grown in the presence of 750 mg/ml of active Geneticin (G418) (Gibco ± BRL, Hamilton, Ontario, Canada).
Antibodies
Polyclonal rabbit anti-mouse CEACAM1 antibodies (either serum 231 or 655) were used to detect the wild-type and mutant forms of CEACAM1. The generation of serum 231 was reported in McCuaig et al., 1992 . Serum 655 was a generous gift of Dr KV Holmes (University of Colorado, USA) and has previously been described (Pensiero et al., 1992) . Drs Kuprina and Rudinskaya (Moscow, Russia) kindly provided us with the AgB10 rat anti-mouse CEACAM1-speci®c monoclonal antibody used in our cyto¯uorometric analyses.
Site-directed mutagenesis
Point and deletion mutations of the CEACAM1-L-cytoplasmic region have previously been described (Huber et al., 1999) . Brie¯y, the D518 deletion mutant was created by inserting a TGA stop codon at position 519. Point mutants Y515F, Y488F, Y488,515F, V518A, 3K?3A were generated by overlap PCR mutagenesis (Vallejo et al., 1994) . The Nterminal deletion mutants for the long and short isoform of CEACAM1 (D4-122/S, D4-122/L) were provided by Dr Gabriela Dveksler (Dveksler et al., 1993) .
Transfections and establishment of stable cell lines
CEACAM1-L, CEACAM1-S and all mutant CEACAM1-L cDNAs were cloned in a pLXSN vector (Kunath et al., 1995) and transfected in C2 packaging cells by calcium phosphate co-precipitation (Southern and Berg, 1982) . Introduction of the cDNAs in CT51 or NIH3T3 cells was accomplished by retroviral-mediated infections (Kunath et al., 1995) . G418 selection was applied on cell populations 48 h post infection. Following G418 selection, CEACAM1-expressing cell populations were immunoselected using the anti-CEACAM1 rabbit polyclonal antibodies (serum 231 or 655) and Dynabeads 1 (Dynal, Great Neck, NY, USA). FACS and Western analyses were carried out to con®rm the expression of CEACAM1 in the immunoselected cells.
Cyto¯uorometric analyses
Surface expression of CEACAM1 proteins was assessed by cyto¯uorometry using rat anti-CEACAM1 monoclonal antibody AgB10 and¯uorescein-labeled goat anti-rat antibody (Cappel). Expression of the CEACAM1/D4-122/L and /D4-122/S mutants was detected with serum 655. Fluorometric detections were analysed with a FACScan Becton-Dickinson program. Fold expression was determined by calculating the ratio of the median expression of cells incubated with both the primary and secondary antibodies over the median expression of cells exposed only to the¯uorochrome-labeled antibody.
Western analyses
Expression of CEACAM1 proteins in protein lysates was veri®ed by immunoblotting. Cells were lifted, pelleted by centrifugation, and resuspended in a lysis buer (50 mM TrisHCl pH 8.0, 5 mM EDTA, 1% Nonidet-P40, 150 mM NaCl and 10 mg/ml of each: leupeptin, aprotinin, pepstatin, Nphenylmethylsulfonyl¯uoride, N-a-p-tosyl-l-lysine chloro-methyl ketone, N-tosyl-1-phenylalanine chloromethyl ketone) and incubated on ice for 10 min. Lysates were centrifuged at 15 000 g for 10 min at 48C. Total protein concentration was evaluated using a BCA Protein Assay kit (Pierce Chemicals, Rockford, IL, USA). Cell lysate proteins (100 mg) were resolved on 8% SDS ± PAGE gels and transferred to Immobilon-P membranes (Millipore). CEACAM1 proteins were detected with either 231 or 655 antibodies at a 1 : 500 dilution and 125 I-labeled protein A. A Fuji BioImager 2000 was used for protein quanti®cation.
Intercellular adhesion assays
Cell aggregation assays were performed using either wild-type NIH3T3 cells or populations stably transfected with either the CEACAM1-L or -S or the D4-122/L or -/S mutant cDNA constructs or an empty control vector. Cells were removed from the tissue culture dishes with a solution of PBS-citrate containing 0.125% trypsin. Single cell suspensions were produced by three passages through 27-gauge needles. Viability of cells was determined by trypan blue dye exclusion and shown to be 495% in every assay. Three million cells of each transfectant clone were incubated in 3 ml of a-MEM medium containing 0.8% fetal bovine serum and DNase I (10 mg/ml) for 2 h at 378C with constant stirring at 100 r.p.m.; samples were retrieved at 30 min intervals and were evaluated by hemocytometer for both single cells and number of cells in aggregate. Standard deviations on the average of one representative experiment were calculated.
Tumorigenicity assays
Four million viable CT51 wild-type or transfected cells resuspended in 200 ml of a-MEM were injected s.c. in thē ank of 6 ± 8 week-old female BALB/c mice, weighing 20 ± 22 g. A minimum of ten mice per cell line were used for each assay. Mice were checked every 5 ± 7 days for tumor growth. The duration of the assay was for 42 ± 69 days depending on the experiment. Mice were sacri®ced, tumors were resected, weighed and measured with calipers. Statistical analysis of our data was done as described in Kunath et al. (1995) .
